Journal of Lipid Research launches junior associate editors program
This year, the Journal of Lipid Research welcomes its first cohort of junior associate editors.
School of Medicine
Research area: Nuclear lipid signaling and structure
Mentor: George Carman
Irving Medical Center
Research area: Regulation and metabolism of Lipoprotein(a)
Mentor: Henry Ginsberg
University of Iowa
Carver College of Medicine
Research area: Lipid metabolism in endothelial cells
Mentor: Stephen Young
University of Pennsylvania Perelman School of Medicine
Research area: Metabolism and lipid droplets in liver disease
Mentor: Nick Davidson
The four assistant professors, chosen from nominations made by the journal’s associate editors, are partnering with senior editors to learn how to manage the peer-review process.
“Engagement with the best and brightest young investigators in the lipid field is an investment in the future of JLR,” Co-Editor-in-Chief Kerry−Anne Rye said.
The new editors — two Ph.D.s and two M.D.s — already have accrued accolades and earned the community’s trust. Two are recipients of the JLR Junior Investigator Award. One won the Journal of Biological Chemistry/Herb Tabor Young Investigator Award. Another is on the Deuel Conference board.
Co-Editor-in-Chief Nicholas Davidson said the program’s mission is two-fold: “It’s demystifying the peer-review process and also teaching what we hope are going to be the next generation of full associate editors.”
The new editors are serving a two-year term from March 1, 2019, to Feb. 28, 2021.
They also will contribute a new type of article to the journal — commentaries on exciting lipid research published elsewhere.
Join the ASBMB Today mailing list
Sign up to get updates on articles, interviews and events.
Despite the recent approval of this drug for use against COVID-19, questions remain as to the efficacy of this treatment.
In the inaugural JBC Methods Madness Tournament, cryo–EM/ET gave structural biologists around the world something to cheer about, beating mass spectrometry 51% to 49% — a margin thinner than shaved ice.
Scientists at eight institutions in the U.S. and Europe have used a protein interaction map to identify 69 drugs that might work against SARS-CoV-2, the virus that causes COVID-19.